In order to construct the zwitterionic structure of phosphorylcholine onto the surface of biomaterials, five novel phospholanes containing hydroxyl group were synthesized from the corresponding diol and 2-chloro-2-oxo...In order to construct the zwitterionic structure of phosphorylcholine onto the surface of biomaterials, five novel phospholanes containing hydroxyl group were synthesized from the corresponding diol and 2-chloro-2-oxo-1,3,2-dioxaphospholane in the presence of THF. Then, five novel phosphorylcholines containing hydroxyl group were prepared by the corresponding phospholane and anhydrous trimethylamine in the presence of acetonitrile. Their structures were characterized by FTIR, 1H NMR and elemental analysis.展开更多
4-羟基-L-脯氨酸、半胱胺盐酸为反应材料,经过一系列的氨基保护、氧化、缩合反应,得到Teneligliptin的关键中间体(2S)-4-氧代-2-(3-噻唑烷基羰基)-1-吡咯烷羧酸叔丁酯,收率可达73.8%。开发了一种全新的合成方式,在氧化阶段进行了改进和...4-羟基-L-脯氨酸、半胱胺盐酸为反应材料,经过一系列的氨基保护、氧化、缩合反应,得到Teneligliptin的关键中间体(2S)-4-氧代-2-(3-噻唑烷基羰基)-1-吡咯烷羧酸叔丁酯,收率可达73.8%。开发了一种全新的合成方式,在氧化阶段进行了改进和创新,对其质量进行控制,整个路线对环境几乎没有污染,并且通过1 H NMR和ESI-MS确认了设备的结构。展开更多
In this paper,(E)1-phenylpropane-1,2-dione2-[O-(2-oxo-2-phenylacetyl)oxime] was synthesized and its photoinitiation property as a photoinitiator is slso studied.It had the similar performance to other commercial photo...In this paper,(E)1-phenylpropane-1,2-dione2-[O-(2-oxo-2-phenylacetyl)oxime] was synthesized and its photoinitiation property as a photoinitiator is slso studied.It had the similar performance to other commercial photoinitiators when it was cured with UV lamp.But it had the best performance when it was cured with sunlight in the presence of oxygen.展开更多
We herein report two crystals based on 2-（imidazo[1,2-a]pyridin-2-yl）-2-oxoacetic acid rad- ical and its perchlorate, and investigate the relationship between magnetic properties and crystal stacking structures or s...We herein report two crystals based on 2-（imidazo[1,2-a]pyridin-2-yl）-2-oxoacetic acid rad- ical and its perchlorate, and investigate the relationship between magnetic properties and crystal stacking structures or supramolecular interactions. 2-（imidazo[1,2-a]pyridin-2-yl）- 2-oxoaeetic acid radical in two crystals mainly exist as diamagnetic dimer formed via short atomic contacts or supramolecular interactions （hydrogen bonds, anion-Tr or lone- pair-~r interactions）, leading to low magnetic susceptibilities. 2-（imidazo[1,2-a]pyridin-2-yl）- 2-oxoaeetic acid radical crystal exhibits quasi-one-dimensional columnar stacking chain and weak antiferromagnetism. However, its perchlorate crystal possesses one-dimensional double- stranded chain structure assembled through double hydrogen bonds and anion-To interactions, and reveals weak ferromagnetism.展开更多
AIM: TO determine whether 2-(3-carboxy-l-oxopropyl) amino-2-deoxy-D-glucose (COPADG), a derivative of D-amino-glucose, inhibited the growth of human esophageal cancer cell line Eca-109. METHODS: Effects of COPADG on E...AIM: TO determine whether 2-(3-carboxy-l-oxopropyl) amino-2-deoxy-D-glucose (COPADG), a derivative of D-amino-glucose, inhibited the growth of human esophageal cancer cell line Eca-109. METHODS: Effects of COPADG on Eca-109 cells cultured in RPMI 1640 medium were examined by a tetrazoliumbased colorimetric assay (MTT assay). RESULTS: COPADG inhibited the growth of Eca-109 cells in a dose- and time-dependent manner; the maximumin hibition rate was 83.75%. CONCLUSION: COPADG can directly inhibit the proliferation of Eca-109 cells, which may serve as the experimental evidence for development of new drugs for esophageal cancer therapy.展开更多
文摘In order to construct the zwitterionic structure of phosphorylcholine onto the surface of biomaterials, five novel phospholanes containing hydroxyl group were synthesized from the corresponding diol and 2-chloro-2-oxo-1,3,2-dioxaphospholane in the presence of THF. Then, five novel phosphorylcholines containing hydroxyl group were prepared by the corresponding phospholane and anhydrous trimethylamine in the presence of acetonitrile. Their structures were characterized by FTIR, 1H NMR and elemental analysis.
文摘4-羟基-L-脯氨酸、半胱胺盐酸为反应材料,经过一系列的氨基保护、氧化、缩合反应,得到Teneligliptin的关键中间体(2S)-4-氧代-2-(3-噻唑烷基羰基)-1-吡咯烷羧酸叔丁酯,收率可达73.8%。开发了一种全新的合成方式,在氧化阶段进行了改进和创新,对其质量进行控制,整个路线对环境几乎没有污染,并且通过1 H NMR和ESI-MS确认了设备的结构。
文摘In this paper,(E)1-phenylpropane-1,2-dione2-[O-(2-oxo-2-phenylacetyl)oxime] was synthesized and its photoinitiation property as a photoinitiator is slso studied.It had the similar performance to other commercial photoinitiators when it was cured with UV lamp.But it had the best performance when it was cured with sunlight in the presence of oxygen.
基金This work was supported by the National Natural Science Foundation of China （No.21172210）.
文摘We herein report two crystals based on 2-（imidazo[1,2-a]pyridin-2-yl）-2-oxoacetic acid rad- ical and its perchlorate, and investigate the relationship between magnetic properties and crystal stacking structures or supramolecular interactions. 2-（imidazo[1,2-a]pyridin-2-yl）- 2-oxoaeetic acid radical in two crystals mainly exist as diamagnetic dimer formed via short atomic contacts or supramolecular interactions （hydrogen bonds, anion-Tr or lone- pair-~r interactions）, leading to low magnetic susceptibilities. 2-（imidazo[1,2-a]pyridin-2-yl）- 2-oxoaeetic acid radical crystal exhibits quasi-one-dimensional columnar stacking chain and weak antiferromagnetism. However, its perchlorate crystal possesses one-dimensional double- stranded chain structure assembled through double hydrogen bonds and anion-To interactions, and reveals weak ferromagnetism.
文摘AIM: TO determine whether 2-(3-carboxy-l-oxopropyl) amino-2-deoxy-D-glucose (COPADG), a derivative of D-amino-glucose, inhibited the growth of human esophageal cancer cell line Eca-109. METHODS: Effects of COPADG on Eca-109 cells cultured in RPMI 1640 medium were examined by a tetrazoliumbased colorimetric assay (MTT assay). RESULTS: COPADG inhibited the growth of Eca-109 cells in a dose- and time-dependent manner; the maximumin hibition rate was 83.75%. CONCLUSION: COPADG can directly inhibit the proliferation of Eca-109 cells, which may serve as the experimental evidence for development of new drugs for esophageal cancer therapy.
